Yu Chen

Prof. Dr. Yu Chen

Materdicine Lab, School of Life Sciences, Shanghai University, Shanghai 200444, China

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2019 in Chemical Reviews
Verified
Journal Article
Closed access
BYBowen Yang
Bowen Yang
Yu ChenYu Chen
Yu Chen
JSJianlin Shi
Jianlin Shi

2 November 2017 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
HLHan Lin
Han Lin
SGShanshan Gao
Shanshan Gao
CDChen Dai
Chen Dai
Yu ChenYu Chen
Yu Chen
JSJianlin Shi
Jianlin Shi

25 August 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
MHMinfeng Huo
Minfeng Huo
LWLiying Wang
Liying Wang
Yu ChenYu Chen
Yu Chen
JSJianlin Shi
Jianlin Shi
Tumor cells metabolize in distinct pathways compared with most normal tissue cells. The resulting tumor microenvironment would provide characteristic physiochemical conditions for selective tumor modalities. Here we introduce a concept of sequential catalytic nanomedicine for efficient tumor therapy by designing and delivering biocompatible nanocatalysts into tumor sites. Natural glucose oxidase (GOD, enzyme catalyst) and ultrasmall Fe3O4 nanoparticles (inorganic nanozyme, Fenton reaction catalyst) have been integrated into the large pore-sized and biodegradable dendritic silica nanoparticles to fabricate the sequential nanocatalyst. GOD in sequential nanocatalyst could effectively deplete glucose in tumor cells, and meanwhile produce a considerable amount of H2O2 for subsequent Fenton-like reaction catalyzed by Fe3O4 nanoparticles in response to mild acidic tumor microenvironment. Highly toxic hydroxyl radicals are generated through these sequential catalytic reactions to trigger the apoptosis and death of tumor cells. The current work manifests a proof of concept of catalytic nanomedicine by approaching selectivity and efficiency concurrently for tumor therapeutics.

30 December 2016 in Nano Letters
Verified
Journal Article
Closed access
HLHan Lin
Han Lin
XWXingang Wang
Xingang Wang
LYLuodan Yu
Luodan Yu
Yu ChenYu Chen
Yu Chen
JSJianlin Shi
Jianlin Shi

20 March 2012 in Journal of the American Chemical Society
Verified
Journal Article
Closed access
LPLimin Pan
Limin Pan
QHQianjun He
Qianjun He
JLJianan Liu
Jianan Liu
Yu ChenYu Chen
Yu Chen
MMMing Ma
Ming Ma
JSJianlin Shi
Jianlin Shi

18 December 2014 in Chemical Society Reviews
Verified
Journal Article
Closed access
PDF file
Yu ChenYu Chen
Yu Chen
CTChaoliang Tan
Chaoliang Tan
HZHua Zhang
Hua Zhang
Liang WangLiang Wang
Liang Wang
The increasing demand of clinical biomedicine and fast development of nanobiotechnology has substantially promoted the generation of a variety of organic/inorganic nanosystems for biomedical applications. Biocompatible two-dimensional (2D) graphene analogues (e.g., nanosheets of transition metal dichalcogenides, transition metal oxides, g-C3N4, Bi2Se3, BN, etc.), which are referred to as 2D-GAs, have emerged as a new unique family of nanomaterials that show unprecedented advantages and superior performances in biomedicine due to their unique compositional, structural and physicochemical features. In this review, we summarize the state-of-the-art progress of this dynamically developed material family with a particular focus on biomedical applications. After the introduction, the second section of the article summarizes a range of synthetic methods for new types of 2D-GAs as well as their surface functionalization. The subsequent section provides a snapshot on the use of these biocompatible 2D-GAs for a broad spectrum of biomedical applications, including therapeutic (photothermal/photodynamic therapy, chemotherapy and synergistic therapy), diagnostic (fluorescent/magnetic resonance/computed tomography/photoacoustic imaging) and theranostic (concurrent diagnostic imaging and therapy) applications, especially on oncology. In addition, we briefly present the biosensing applications of these 2D-GAs for the detection of biomacromolecules and their in vitro/in vivo biosafety evaluations. The last section summarizes some critical unresolved issues, possible challenges/obstacles and also proposes future perspectives related to the rational design and construction of 2D-GAs for biomedical engineering, which are believed to promote their clinical translations for benefiting the personalized medicine and human health.